



HHS Public Access

Author manuscript

J Clin Cell Immunol. Author manuscript; available in PMC 2016 July 08.

Published in final edited form as:

J Clin Cell Immunol. 2016 June ; 7(3): . doi:10.4172/2155-9899.1000422.

Matrix Metalloproteinase-9 Production by Immortalized Human Chondrocyte Lines

Charles J. Malemud^{1,*,#}, Evan C. Meszaros¹, Meredith A. Wylie¹, Wissam Dahoud^{2,3}, Yelenna Skomorovska-Prokvolit², and Sam Mesiano²

¹Department of Medicine, Division of Rheumatic Diseases, Case Western Reserve University, School of Medicine, Cleveland, Ohio 44106, USA

²Department of Reproductive Biology, Case Western Reserve University, School of Medicine, Cleveland, Ohio 44106, USA

³Department of Pathology, Institute of Pathology, Case Western Reserve University, School of Medicine, University Hospitals Case Medical Center, Cleveland, Ohio 44106, USA

Abstract

We reported at the Keynote Forum of Immunology Summit-2015 that recombinant human (rh) TNF- α or rhIL-6 stimulated production of matrix metalloproteinase-9 (MMP-9) in the T/C28a2 and C-28/I2 human immortalized chondrocyte cell lines. Furthermore, we reported that tocilizumab (TCZ), a fully humanized monoclonal antibody which neutralizes IL-6-mediated signaling, inhibited the rhIL-6-mediated increase in the production of MMP-9. IL-6 is also a known activator of the JAK/STAT signaling pathway. In that regard, we evaluated the effect of rhIL-6 on total and phosphorylated Signal Transducer and Activator of Transcription by these chondrocyte lines which showed that whereas STAT3 was constitutively phosphorylated in T/C28a2 chondrocytes, rhIL-6 activated STAT3 in C-28/I2 chondrocytes. The finding that rhIL-6 increased the production of MMP-9 by human immortalized chondrocyte cell lines may have important implications with respect to the destruction of articular cartilage in rheumatoid arthritis and osteoarthritis. Thus, the markedly elevated level of IL-6 in rheumatoid arthritis and osteoarthritis sera and synovial fluid would be expected to generate significant MMP-9 to cause the degradation of articular cartilage extracellular matrix proteins. The finding that TCZ suppressed rhIL-6-mediated MMP-9 production suggests that TCZ, currently employed in the medical therapy of rheumatoid arthritis, could be considered as a drug for osteoarthritis.

Keywords

Chondrocytes; Human; Matrix metalloproteinases; Osteoarthritis; Pro-inflammatory cytokines; Rheumatoid arthritis; Signal transduction

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

*Corresponding author: Charles J. Malemud, Ph.D., Professor of Medicine, Department of Medicine, Division of Rheumatic Diseases, University Hospitals Case Medical Center, Foley Medical Building, 2061 Cornell Road, Room 207, Cleveland, Ohio 44106-5076, USA, Tel: 216-844-7846, 216-536-1945; Fax: 216-844-2288; cjm4@cwru.edu.

#Editor-in-Chief of the Journal of Clinical and Cellular Immunology

Conflict of Interest Statement: The authors declare no conflict of interest.

Introduction

Although it is acknowledged that the pathologic mechanisms that contribute to rheumatoid arthritis (RA) and osteoarthritis (OA) are significantly different, there are overlapping pathophysiological components which are characteristic of each disease process [1]. Most prominent of these overlapping characteristics of OA and RA is the significant increase in the serum and synovial fluid levels of pro-inflammatory cytokines, exemplified by tumor necrosis factor- α (TNF- α), interleukin-1 β (IL-1 β) and IL-6 [2,3]. Thus, presumably acting in concert these pro-inflammatory cytokines can cause 1) matrix metalloproteinase (MMP) gene expression to be up-regulated; 2) decreased synthesis of extracellular matrix (ECM) proteins, such as Type II collagen and aggrecan; and 3) induction of chondrocyte apoptosis [1].

The pro-inflammatory cytokines, IL-6 and TNF- α , are considered most integral in perpetuating the inflammatory response in RA and OA [2,3]. IL-6 and TNF- α also play a role in up-regulating MMP gene expression as well [4-6]. In that regard, the MMPs most often associated with chronic inflammation characteristic of RA and OA are MMP-1 (collagenase-1), MMP-2 (72kDa gelatinase), MMP-3 (stromelysin-1), MMP-10 (stromelysin-2), and MMP-9 (92kDa gelatinase) [6]. MMP-9 appears to be particularly critical for the progression of both RA and OA pathology primarily because MMP-9 possesses broad ECM protein substrate specificity. Thus, MMP-9 is a potent enzyme mediator of cartilage destruction based on the accumulation of evidence which showed that MMP-9 could efficiently degrade many of the articular cartilage ECM proteins that are critical for maintaining the structural integrity of this musculoskeletal tissue [7-10].

Despite recent basic research advances and clinical findings which has vastly improved our understanding of the role of pro-inflammatory cytokines and MMPs in RA and OA disease pathogenesis and progression, a detailed understanding of which mechanism(s) contribute to the capacity of TNF- α or IL-6 to produce these changes in human chondrocyte MMP-9 remains to be elucidated. Thus, the collection of results from experimental studies presented at the Keynote Forum at Immunology Summit-2015 reported on the extent to which recombinant human TNF- α (rhTNF- α) or rhIL-6 altered MMP-9 production by human chondrocyte immortalized cell lines. A second line of evidence presented at Immunology Summit-2015 showed that tocilizumab (TCZ), a fully humanized monoclonal antibody, which neutralizes the activity of IL-6 *via* IL-6R α /gp130 or by interacting with membrane-bound IL-6R (absent the gp130 component) or with the soluble IL-6 receptor (sIL-6R), reduced MMP-9 production by the immortalized human chondrocyte lines in the presence of recombinant human (rh) IL-6.

Materials

The materials used in these studies were reviewed at Immunology Summit-2015. Thus, the immortalized human chondrocyte cell lines, T/C28a2 and C-28/I2, were provided by Drs. Mary Goldring and Miguel Otero (The Hospital for Special Surgery, Weill Medical College of Cornell University). These immortalized human chondrocyte lines had previously been

shown to synthesize several “signature” ECM proteins of human cartilage [11-13] as well as the cartilage-specific transcription factor, SOX9 [12].

PANC-1, a pancreatic tumor cell line was obtained from the American Type Culture Collection. PANC-1 was incubated with phorbol myristate acetate. PANC-1 was employed as the positive control for MMP-9 production [14]. The pro-inflammatory cytokines, rhIL-6 and rhTNF- α were obtained from various commercial vendors as was sIL-6R as previously described [14]. U0126, a small molecule inhibitor of MEK1/2, an upstream protein kinase required for the phosphorylation of ERK1/2 was purchased from Cell Signaling Technology. The Signal Transducer and Activator of Transcription-3 (U-STAT3) antibodies were purchased from R&D Systems and the β -actin antibody from Cell Signaling Technology [15]. An antibody which interacts with human neutrophil gelatinase-associated lipocalin (NGAL) was purchased from Pierce Biotechnology [14]. WHI-P131 (Janex-1) was from Cayman Chemicals. Tocilizumab (TCZ) was obtained through a contract between Case Western Reserve University and Genentech/Roche Group.

Methods

We thoroughly reviewed the methodology at Immunology Summit-2015 which was employed for these studies. MMP-9 production was measured by an MMP-9 ELISA using our now published method [14]. MMP-9 production was also assessed by immunocytochemical (ICC) localization of MMP-9 in C-28/I2 chondrocytes [14]. The presence of NGAL was also determined by ICC [14]. In addition, the experimental details for analyzing MMP-9 production as well as for the detection of STAT proteins by western blotting were performed as described in 2 papers published following the Keynote Presentation at Immunology Summit-2015 [14,15].

Results

We reported at Immunology Summit-2015 that MMP-9 production was significantly increased by rhIL-6 (50ng/ml) or by rhTNF- α (20ng/ml) in both T/C28a2 and C-28/I2 chondrocyte cell lines as well as by PANC-1 cells treated with phorbol myristate acetate. We also noted that MMP-9 production by these chondrocytes after incubation with rhTNF- α was far more robust compared to rhIL-6. We noted that TCZ (200 ng/ml) inhibited rhIL-6-stimulated, but not rhTNF- α -induced MMP-9 production, after 1 and 4 hrs. However, higher concentrations of TCZ (i.e. 400-800 ng/ml) did not appreciably increase the inhibition of MMP-9 when combined with rhIL-6 (50 ng/ml) for 1 or 4 h [14]. The ICC analysis confirmed the MMP-9 ELISA data. Thus, we reported that in the presence of rhIL-6 the number of MMP-9-positive C-28/I2 chondrocytes was reduced by both TCZ (200 ng/ml) as well as by sIL-6R (50 ng/ml), whereas the combination of rhIL-6 plus sIL-6R significantly increased the number of MMP-9-positive chondrocytes compared to sIL-6R alone [14].

We had previously reported that NGAL existed in a complex with MMP-9 in synovial fluid sampled from OA patients prior to undergoing joint replacement surgery [10]. In addition, we previously showed that the NGAL/MMP-9 complex protected MMP-9 from autodegradation [10]. At Immunology Summit-2015, we reported that the level of

immunoreactive NGAL as determined by ICC was decreased after treatment of C-28/I2 chondrocytes with sIL-6R (50 ng/ml) or after incubation with the combination of rhIL-6 (50 ng/ml) plus TCZ (200 ng/ml) when compared to a “no-additions” control group, but not when compared to rhIL-6 alone. Of note, the combination of rhIL-6 plus TCZ did not reduce NGAL-positive chondrocytes compared to rhIL-6 alone.

We also showed western blots at Immunology summit-2015 demonstrating that STAT1 was constitutively phosphorylated in the T/C28a2 chondrocyte line [16]. However, C-28/I2 chondrocytes incubated with rhIL-6 (50 ng/ml) resulted in the phosphorylation of STAT3 without changing total STAT3 [15]. Moreover, the combination of rhIL-6 and the pan-JAK-small molecule inhibitor, Janex-1 (100 μ M), resulted in the complete loss of the anti-p-STAT3 antibody reactive band [15]. In addition, western blot analyses shown at Immunology Summit-2015 indicated that besides total STAT3 (U-STAT3) which migrated to a position similar to authentic U-STAT3 (i.e. 75 kDa) often termed STAT3 α as previously reported [17], a slightly faster migrating anti-STAT3 antibody reactive band was also detected [15].

At the Immunology Summit-2015 Keynote presentation we proposed that although IL-6 was known to preferentially activate the JAK/STAT pathway [17], IL-6 could also potentially activate components of the SAPK/MAPK pathway as well. To examine this possibility we showed that C-28/I2 chondrocytes produced 2 isoforms of phosphorylated-p38kinase which were identified on western blots with a p-p38kinase- α antibody. These p-p38kinase- α isoforms were p-p38kinase-55kDa and p-p38kinase-38kDa [18]. However, treatment of C-28/I2 chondrocytes with rhIL-6 for 30 min did not alter the signal intensity of either of the p-p38kinase- α isoforms. Of note, the combination of rhIL-6 (50 ng/ml) and U0126 (10 μ M or 20 μ M) reduced the signal intensity of both p-p38kinase isoforms [18].

Discussion

To summarize the results of these *in vitro* studies presented at Immunology Summit-2015 we showed that TCZ, a monoclonal antibody that neutralizes the activity of IL-6 mainly *via* IL-6/IL-6R α /gp130 signaling, inhibited rhIL-6-stimulated MMP-9 production in the immortalized human chondrocyte cell lines, T/C28a2 and C-28/I2, whereas the combination of rhTNF- α and TCZ did not inhibit MMP-9 production [14]. Thus, the results of these *in vitro* analyses may have important implications for the future therapy of OA for suppressing MMP-9 production by articular chondrocytes.

Furthermore, sIL-6R also reduced the number of MMP-9-positive C-28/I2 chondrocytes in the presence of rhIL-6 [14]. Thus, in addition to rhIL-6-mediated activation of the IL-6/IL-6R α /gp130 and IL-6/mIL-6R pathways we proposed at Immunology Summit-2015 that a signaling pathway activated when IL-6 interacts with sIL-6R was also likely to be involved in IL-6-mediated chondrocyte MMP-9 production. Furthermore, based on this data as well as other evidence published from our laboratory [15], we proposed that neutralizing the IL-6-mediated stimulation of chondrocyte MMP-9 with TCZ or administration of an exogenous sIL-6R fusion protein could ultimately become another medical strategy for suppressing articular cartilage ECM protein degradation in OA or RA.

We had previously shown using a quantitative immunoblot analysis that rhIL-6, rhTNF- α or sIL-6R activated STAT3 protein in human immortalized chondrocyte cell lines [15,16]. We had also shown that incubating human chondrocytes enzymatically liberated from OA knee cartilage with rhTNF- α (10 ng/ml) resulted in the phosphorylation of U-STAT3 (p-STAT3) without altering total U-STAT3 α [19]. This data also provided direct evidence that rhTNF- α (which is not commonly associated with activation of JAK/STAT signaling), could activate U-STAT3 in these immortalized human chondrocytes as well as in cultured human OA chondrocytes.

The results of western blots also indicated that additional STAT protein isoforms were produced by these human chondrocyte cell lines. These STAT protein isoforms reacted with anti-U-STAT or anti-p-STAT antibodies and migrated faster than authentic U-STAT proteins [15]. However, at the very least we confirmed in that study [15] that these faster migrating STAT isoforms did not result from proteolysis during the processing of chondrocyte protein lysates employed for these western blots.

It may also be noteworthy in the present context that the faster migrating STAT proteins may turn out to be truncated STAT proteins which were previously found to be produced by myeloid leukemia cells where a truncated isoform of STAT3 (e.g. STAT3 β) [20] was eventually traced to the activity of a serine-dependent protease produced by these cells acting on STAT3 α [21]. Following that discovery, a protease-mediated truncation of the COOH-terminal transactivation domain of STAT3 α was found to be the molecular mechanism responsible for the truncated STAT3 β isoform [22]. More recently, Timofeeva et al. [23] reported the existence of a 67.5 kDa truncated U-STAT3 isoform which appeared to recognize single-stranded spacers within cruciform DNA structures. This truncated STAT3 isoform was abundant in the nuclei of cancer cells and due to this finding Timofeeva et al. [23] also suggested that the truncated U-STAT3 isoform could play a role in the organization of chromatin and gene expression in these cells. However, presently we do not know if any relationship exists between the faster migrating isoform of U-STAT3 produced by the C-28/I2 immortalized human chondrocyte cell line and any of the truncated form(s) of U-STAT3 and p-STAT3 produced by cancer cells. This will in all likelihood require further in-depth analysis going forward to determine the extent to which the faster migrating STAT3 isoform produced by this human immortalized chondrocyte cell line arises from a post-synthesis enzymatic processing of U-STAT3 α or by synthesis from alternatively spliced U-STAT3 α mRNA.

Acknowledgments

This study was supported, in part, by contract #ACT077 between Case Western Reserve University (CWRU) [CJ Malemud, Principal Investigator] and Genentech/Roche Group, by the CWRU Visual Sciences Research Core Center Grant (EY-P30-11373) and by grant NICHD R01-069819-01A1 (S Mesiano, Principal Investigator).

References

1. Malemud CJ, Schulte ME. Is there a final common pathway for arthritis? *Future Rheumatol.* 2008; 3:253–268.
2. Malemud CJ, Reddy SK. Targeting cytokines, chemokines and adhesion molecules in rheumatoid arthritis. *Curr Rheum Rev.* 2008; 4:219–234.

3. Malemud CJ. Anticytokine therapy for osteoarthritis: evidence to date. *Drugs Aging*. 2010; 27:95–115. [PubMed: 20104937]
4. Martel-Pelletier J, Welsch DJ, Pelletier JP. Metalloproteases and inhibitors in arthritic diseases. *Best Pract Res Clin Rheumatol*. 2001; 15:805–829. [PubMed: 11812023]
5. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. *Front Biosci*. 2006; 11:529–543. [PubMed: 16146751]
6. Malemud, CJ. Regulation of chondrocyte matrix metalloproteinase gene expression. In: Dhalla, NS.; Chakraborti, S., editors. *Proteases in Health and Diseases*. Springer Science; New York: 2013. p. 63-77.
7. Malemud CJ, Islam N, Haqqi TM. Pathophysiological mechanisms in osteoarthritis lead to novel therapeutic strategies. *Cells Tissues Organs*. 2003; 174:34–48. [PubMed: 12784040]
8. Malemud CJ. Matrix metalloproteinases (MMPs) in health and disease: an overview. *Front Biosci*. 2006; 11:1696–1701. [PubMed: 16368548]
9. Toth M, Sohail A, Fridman R. Assessment of gelatinases (MMP-2 and MMP-9) by gelatin zymography. *Methods Mol Biol*. 2012; 878:121–135. [PubMed: 22674130]
10. Gupta K, Shukla M, Cowland JB, Malemud CJ, Haqqi TM. Neutrophil gelatinase-associated lipocalin is expressed in osteoarthritis and forms a complex with matrix metalloproteinase 9. *Arthritis Rheum*. 2007; 56:3326–3335. [PubMed: 17907186]
11. Kokenyesi R, Tan L, Robbins JR, Goldring MB. Proteoglycan production by immortalized human chondrocyte cell lines cultured under conditions that promote expression of the differentiated phenotype. *Arch Biochem Biophys*. 2000; 383:79–90. [PubMed: 11097179]
12. Finger F, Schörlle C, Zien A, Gebhard P, Goldring MB, et al. Molecular phenotyping of human chondrocyte cell lines T/C-28a2, T/C-28a4, and C-28/I2. *Arthritis Rheum*. 2003; 48:3395–3403. [PubMed: 14673991]
13. Goldring MB. Culture of immortalized chondrocytes and their use as models of chondrocyte function. *Methods Mol Med*. 2004; 100:37–52. [PubMed: 15280586]
14. Meszaros EC, Dahoud W, Mesiano S, Malemud CJ. Blockade of recombinant human IL-6 with tocilizumab suppresses matrix metalloproteinase-9 production in the C28/I2 immortalized human chondrocyte cell line. *Integr Mol Med*. 2015; 2:304–310. [PubMed: 26753098]
15. Meszaros EC, Malemud CJ. Phosphorylation of STAT proteins by recombinant human IL-6 in immortalized human chondrocyte cell lines, T/C28a2 and C28/I2. *Int J Interferon, Cytokine, Mediator Res*. 2015
16. Meszaros EC, Malemud CJ. STAT1 is constitutively activated in the T/C28a2 immortalized juvenile human chondrocyte line and stimulated by IL-6 plus soluble IL-6R. *J Clin Cell Immunol*. 2015; 6:307. [PubMed: 26213636]
17. Ng IH, Ng DC, Jans DA, Bogoyevitch MA. Selective STAT3- α or - β expression reveals spliceform-specific phosphorylation kinetics, nuclear retention and distinct gene expression outcomes. *Biochem J*. 2012; 447:125–136. [PubMed: 22799634]
18. Wylie MA, Meszaros EC, Malemud CJ. The effect of interleukin-6-type cytokines and adiponectin on MAPK activation in the immortalized human chondrocyte C28/I2 line and normal human chondrocytes. *J Cell Biol Histol*. 2015; 1:101.
19. Malemud CJ, Sun Y, Pearlman E, Ginley NM, Awadallah A, et al. Monosodium urate and tumor necrosis factor- α increase apoptosis in human chondrocyte cultures. *Rheumatology (Sunnyvale)*. 2012; 2:113.
20. Xia Z, Sait SN, Baer MR, Barcos M, Donohue KA, et al. Truncated STAT proteins are prevalent at relapse of acute myeloid leukemia. *Leuk Res*. 2001; 25:473–482. [PubMed: 11337019]
21. Xia Z, Salzler PR, Kunz DP, Baer MR, Kazim L, et al. A novel serine-dependent proteolytic activity is responsible for truncated signal transducer and activator of transcription proteins in acute myeloid leukemia blasts. *Cancer Res*. 2001; 61:1747–1753. [PubMed: 11245492]
22. Benekli M, Baumann H, Wetzler M. Targeting signal transducer and activator of transcription signaling pathway in leukemias. *J Clin Oncol*. 2009; 27:4422–4432. [PubMed: 19667270]
23. Timofeeva OA, Chasovskikh S, Lonskaya I, Tarasova NI, Khavrutskii L, et al. Mechanisms of unphosphorylated STAT3 transcription factor binding to DNA. *J Biol Chem*. 2012; 287:14192–14200. [PubMed: 22378781]